New oral drug enters human testing for devastating ALS
NCT ID NCT07396818
Summary
This early-stage study is testing a new oral drug called Kamlanoflast in 40 people with ALS (amyotrophic lateral sclerosis). The main goals are to check if the drug is safe and tolerable when taken for 24 weeks, and to see how it affects markers of inflammation and physical function. The study will also measure breathing capacity and drug levels in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.